The activation of LKB1/AMPK inhibits the migration of TGF-β–stimulated cancer cells by inhibiting Smad2/3 activity, which suggests that AMPK may be a target for cancer drug therapy [42]. This evidence concerns the gene TGFB1 and cancer.